4//SEC Filing
Lazarus Alon 4
Accession 0000899243-21-018111
CIK 0001785530other
Filed
May 3, 8:00 PM ET
Accepted
May 4, 4:30 PM ET
Size
19.5 KB
Accession
0000899243-21-018111
Insider Transaction Report
Form 4
Lazarus Alon
Director
Transactions
- Award
Stock Option (right to buy)
2021-04-30+23,200→ 23,200 totalExercise: $16.00Exp: 2031-04-29→ Common Stock (23,200 underlying) - Purchase
Common Stock
2021-05-04$16.00/sh+400,000$6,400,000→ 2,046,634 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-05-04−3,560,551→ 0 total(indirect: See footnote)→ Common Stock (410,717 underlying) - Conversion
Common Stock
2021-05-04+1,235,917→ 1,235,917 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-05-04−10,714,284→ 0 total(indirect: See footnote)→ Common Stock (1,235,917 underlying) - Conversion
Common Stock
2021-05-04+410,717→ 1,646,634 total(indirect: See footnote) - Purchase
Series B Preferred Stock
2020-12-23$0.92/sh+3,560,551$3,280,692→ 3,560,551 total(indirect: See footnote)→ Common Stock (410,717 underlying)
Footnotes (5)
- [F1]On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]The securities are held directly by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. The Reporting Person is the Biotech Investment Manager of the Fund and, as a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd., Mr. Arkin and the Reporting Person may be deemed to share voting and investment power with respect to the shares held by the Fund.
- [F3]On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F4]The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F5]The option was granted on April 30, 2021. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter.
Documents
Issuer
Werewolf Therapeutics, Inc.
CIK 0001785530
Entity typeother
Related Parties
1- filerCIK 0001808244
Filing Metadata
- Form type
- 4
- Filed
- May 3, 8:00 PM ET
- Accepted
- May 4, 4:30 PM ET
- Size
- 19.5 KB